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telemedicine strategies on type 
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meta-analysis
Shaun Wen Huey Lee  1,2, Carina Ka Yee Chan3, Siew Siang Chua4,5 & Nathorn 
Chaiyakunapruk1,2,6
The effects of telemedicine strategies on the management of diabetes is not clear. This study aimed 
to investigate the impact of different telemedicine strategies on glycaemic control management 
of type 2 diabetes patients. A search was performed in 6 databases from inception until September 
2016 for randomized controlled studies that examined the use of telemedicine in adults with type 2 
diabetes. Studies were independently extracted and classified according to the following telemedicine 
strategies: teleeducation, telemonitoring, telecase-management, telementoring and teleconsultation. 
Traditional and network meta-analysis were performed to estimate the relative treatment effects. A 
total of 107 studies involving 20,501 participants were included. Over a median of 6 months follow-up, 
telemedicine reduced haemoglobin A1c (HbA1c) by a mean of 0.43% (95% CI: −0.64% to −0.21%). 
Network meta-analysis showed that all telemedicine strategies were effective in reducing HbA1c 
significantly compared to usual care except for telecase-management and telementoring, with mean 
difference ranging from 0.37% and 0.71%. Ranking indicated that teleconsultation was the most 
effective telemedicine strategy, followed by telecase-management plus telemonitoring, and finally 
teleeducation plus telecase-management. The review indicates that most telemedicine strategies can 
be useful, either as an adjunct or to replace usual care, leading to clinically meaningful reduction in 
HbA1c.
Diabetes mellitus is fast becoming a global public health challenge. It is estimated that more than 415 million peo-
ple worldwide have diabetes, representing nearly 9.1% of the global adult population, and this number is expected 
to increase by more than half to 642 million by the year 20401. Diabetes is no longer a disease of the affluent, as 
nearly 77% of the world’s diabetes population lives in low and middle-income countries, and consumes nearly 
USD 548 billion in health care expenditure globally2,3.
To combat this pandemic, a multi-faceted approach is necessary. Currently, various policy initiatives have 
been suggested to cope with this transformation. These include a comprehensive framework for diabetes preven-
tion, integrating individual-level factors with environmental and policy factors at a macro-level4. At the patient 
level, a coordinated approach which integrates the beneficial effects of monitoring, education and support by 
health care professionals is needed. Telemedical care, or the use of telecommunication for healthcare delivery 
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holds the promise to complement medical management in people with diabetes since it could facilitate early 
detection, diagnosis, monitor disease progression and management5–8. These can range from simple remote mon-
itoring systems9 to more complex Web-based systems which can coordinate, manage and educate patients10.
Previous reviews of telemedicine studies in diabetes have been published, but most of them focused on spe-
cific telemedicine interventions such as telemonitoring11, teleconsultation6 or using interventions delivered by 
computer12. This has delayed potential translation of evidence to changes in policy and practice. This study aimed 
to review the literature regarding telemedicine comprehensively and determine the relative effectiveness of the 
various telemedicine technologies in an outpatient setting.
Methods
Literature search. A systematic review was conducted on the following databases since inception until 
September 30, 2016: MEDLINE, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials, Web of 
Science, and CINAHL Plus, using a combination of keywords and MeSH terms. This was supplemented with 
manual search for citations in reference lists of retrieved articles, textbooks, grey literature as well as conference 
abstracts (Supplemental Table S1). The full list of databases and search terms used are presented in the Appendix 
and documented online (PROSPERO registry CRD42015023913).
Eligibility criteria. Studies were included if they were: (1) randomized controlled studies (RCT); (2) exam-
ined the use of telemedicine, defined as the use of medical exchange between different sites via electronic com-
munications to improve patients’ health status; (3) conducted in ambulatory type 2 diabetes patients; and (4) 
generated content to improve one or more diabetes self-management domains through feedback, advice, rein-
forcement, goal setting or patient decision support.
Data extraction. Data were independently extracted by two reviewers and any discrepancies were resolved 
through adjudication. Information extracted included study characteristics, study participants, eligibility criteria, 
as well as details of intervention and outcome measures. When more than one comparison group was evaluated 
in the RCT, data for the most intensive treatment were extracted. Most of the reported outcomes were reported as 
mean changes, but in some cases as pre-post intervention or percentage of change. In the latter cases, the pre-post 
intervention standard deviations along with a correlation were used to derive the difference along with their 
standard deviations. For assessment of study quality, the Cochrane risk of bias tool13 was used.
Content of intervention and control conditions. Since a wide variety of interventions had been tested 
with the goal of improving quality of care among type 2 diabetes patients, the interventions were characterized 
according to their telemedicine strategies as described in Table 1, based upon an adaptations from the American 
Telemedicine Association14, Tricco et al.15 and Lee et al.16.
In addition, interventions were also coded based on the technology used to support the care delivery process 
and psychological intervention based on the taxonomy described by Welton17 (Supplemental Table S2).
Telemedicine strategy targeting patient
Teleeducation
Any intervention that utilizes application of information and 
communication technologies (e.g. telephone lines, internet) for 
the delivery of distance learning, teaching or training to remote 
participants.
Teleconsultation
Two way communication between a health care provider / specialist 
and patients or between clinicians using a range of communication 
and information technologies (email, phone, automated messaging 
system, Internet or other equipment without face-to-face contact) 
that aim to provide health care at a distance. The interaction is 
directed at patient care from the clinician and communication is 
interactive and occurs within an episode of care.
Telemonitoring
Any process which uses an audio, video or telecommunication and 
electronic information to monitor health status of a patient from a 
distance which is then transmitted back to the clinician. This strategy 
is strictly based on clinical data and excludes clinical skills.
Telecase-management
A collaborative approach that focuses on the coordination, 
integration and direct delivery of beneficiary services provided in 
collaboration with or supplementary to primary care for improving 
the efficiency, depth or breadth of clinical care.
Telementoring
Process of using either audio, video or any telecommunication and 
electronic information processing technology by a person who has 
gone through a specific experience to provide individual guidance, 
mentorship or direction to another person who is new to the 
experience.
Table 1. Taxonomy of classification used in the current study.
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Outcomes and effect modifiers. The primary outcome of interest was glycaemic control based on the 
absolute change in HbA1c from baseline to end of study. Secondary outcomes included changes in cardiovascular 
risk factors (blood pressure, serum lipid profiles, fasting blood glucose and body weight). The study characteris-
tics were also considered as potential effect modifiers in the current study, including sample size, study location, 
delivery mechanisms, study duration as well as baseline HbA1c.
Statistical analyses. For studies that provided sufficient information on glycaemic control (HbA1c or 
fasting plasma glucose), a permutation based meta-analysis with random effects model18 was performed. This 
permutation test was chosen since the method has been found to be useful to reduce the false-positive rates as 
significant heterogeneity is expected as well as the large number of covariates which are expected to be effect 
modifiers in this study19. Statistical heterogeneity was evaluated by using the I2 statistics20. When heterogeneity 
was present, a random-effects meta-regression analysis21 was performed to take into account the clinical (e.g. 
baseline HbA1c, duration of study, study year) and methodological variations (e.g. type of telemedicine, mode 
of telemedicine delivery, medication changes allowed) which could affect the effects of telemedicine on HbA1c.
Subsequently, a multivariable model was constructed, and the goodness-of-fit was determined for each model 
using the adjusted R2, denoting the proportion of between-study-variation explained by the covariates21. The 
variables investigated in the model as possible sources of inconsistencies and/or heterogeneity are: age of publi-
cation, number of participants, location of study (by region), study duration as well as baseline mean HbA1c of 
all participants at entry. In the analysis, the dependent (outcome variable) was the study-level effect size or mean 
difference of HbA1c between the intervention and the control arms. For all other variables that were imputed into 
the model, the mean of each variables were used in the meta-regression analyses.
A network meta-analysis was conducted which combined direct and indirect effects of various treatments 
using the network command in STATA22–25. This allowed the simultaneous comparison of several interventions, 
thus increasing precision and also to evaluate their relative effectiveness, using the resampling-based surface 
under the cumulative ranking curve (SUCRA) and mean ranks26. The results were subsequently presented 
with 95% confidence intervals (CIs)26. Inconsistency checks were performed for closed loop in the network27. 
This was performed based upon the assumption of a common heterogeneity parameter across all loops in the 
network as derived from the network meta-analysis model. We also ran the design-by-treatment interaction 
model to assess the presence of inconsistencies across the entire network23. Publication bias was evaluated vis-
ually using funnel plots and quantified. Forest plots were used to summarize pooled treatment comparison and 
comparison-adjusted funnel plots for small study effects. All analyses were performed using Stata software ver-
sion 13.0 (Stata Inc, College Station, Texas).
Results
Description of studies. Information from the database search yielded 6,660 potentially relevant studies, of 
which 209 full-text were assessed for eligibility. One hundred and seven publications, which included 20,501 ran-
domly assigned participants fulfilled the inclusion criteria and were included in the current review (Supplemental 
Figure S1). All studies were published between 1998 and 2016, and a large proportion had fewer than 100 partic-
ipants (n = 38, 36%). The reported mean age of participants was between 42 to 71 years, mean duration of type 2 
diabetes ranged from 2 to 24 years and median HbA1c was 8.1% at baseline. More than half of these studies were 
conducted in North America (50.5%) and most studies included both male and female participants. Majority of 
the studies were only for short term, with a median follow-up period of 6 months or less (66.7%).
These telemedicine interventions varied as the trials had used a variety of platform for communication and 
delivery of intervention, including telephone (42%), the internet (34%), mobile phones (13%), SMS (9%), video 
conferencing (7%), computer (4%) as well as pagers (1%). These studies had incorporated elements of behav-
ioural therapy (90%), educational counselling (84%), psychosocial support (21%; e.g. peers), cognitive therapy 
(17%) or financial incentives (3%) as part of the intervention component (Table 2, Supplemental Tables S3–S7). 
Intervention providers include nurses (48%), physicians (17%), allied healthcare professionals (15%; pharmacist, 
dieticians), as well as non-specialised support workers (19%; including lay person, social workers and community 
health care workers). In addition, the definition of usual care provided by each of these studies also varied. Many 
of these studies, usual care was defined as regular follow-up or practice of the particular site. In most of these 
studies, they include general diabetes education (29%) and self-monitoring of blood glucose (9%). The details of 
usual care provided to participants was not reported in 52% of trials. Full details of the components for usual care/
control and intervention of each study can be found in Supplemental Tables S3–S7.
In terms of risk of bias assessment, 67 (64%) studies had adequate reporting on sequence generation, 69 (66%) 
studies described loss to follow-up, while only 40 (38%) studies reported intention-to-treat population in their 
analyses (Supplemental Figure S2).
Primary outcome. Pairwise meta-analysis. Telemedicine was superior to usual care in improving HbA1c 
levels, with a mean difference (MD) of −0.43% (95% CI: −0.64% to −0.21%; p < 0.001), but there was substantial 
heterogeneity (Q = 88,052, I2 = 99.9%, H2 = 966; p < 0.001). Subgroup analysis revealed that larger effects were 
observed in studies with shorter intervention duration (≤3 months: −0.65% [−0.91% to −0.39%]; 4–6 months: 
−0.38% [−0.85 to 0.09%]; 7–12 months: −0.62% [−0.91% to −0.34%]; and −0.23% [−0.35% to −0.11%], 
Table 3).
Overall, heterogeneity in the pairwise meta-analysis was high and thus meta-regression analyses were con-
ducted to determine the sources of heterogeneity (see below). No statistically significant inconsistency was indi-
cated in most loops within the network for all outcomes examined.
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Eligible studies
No. of studies 107
Median (IQR) study duration (months) 6 (6–12)
Participant demographics
Total participants 20,467
Median (IQR) age (years) 57 (53–61)
Median (IQR) duration of diabetes (years) 9·6 (7·8–12·3)
No. of male participants, n (%) 8,564 (50·4)









Primary care based 56







Tele-education & Telecase-management 12
Tele-education & Telemonitoring 8
Tele-management & Telemonitoring 12
Tele-management & Teleconsultation 1
Study outcome examined*
HbA1c 94 (88%)
Fasting plasma glucose 24 (22%)
Total cholesterol 32 (30%)
Low density lipoprotein 32 (30%)
High density lipoprotein 31 (29%)
Triglycerides 31 (29%)
Systolic blood pressure 36 (34%)
Diastolic blood pressure 30 (28%)
Body mass index 27 (25%)
Medium of communication used*
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Moderation of effectiveness of study features and intervention mechanisms. In studies which 
were conducted in Asia, a greater reduction in HbA1c values was noted compared to studies conducted in Europe 
or North America (MD: −0.84% vs. −0.20%, p < 0.001). Effect sizes were not significantly different when other 
key features (e.g. baseline HbA1c, study sample size) or interventional content (e.g. interactive vs. non-interactive, 
different psychological intervention content) were examined (Table 3, Supplemental Table S8). Similarly, none of 
the items from the Cochrane risk of bias tool were significant effect modifier but studies that reported high loss to 
follow-up (≥20%) had smaller MD in HbA1c Ncompared to trials with low loss to follow-up (<20%).
Since the providers of intervention (e.g. doctor, nurse) and study duration were reported in less than 5 trials 
of different telemedicine platform, it was not possible to use the meta-regression to evaluate the merits of these 
covariates.
Network meta-analyses. Ninety-three trials (16,978 participants) contributed to the network meta-analyses 
(Figure S3a, appendix). All telemedicine strategies except telementoring and telecase-management reduced 
HbA1c significantly compared to usual care (Fig. 1). However, none of the strategies were significantly better 
than another (Supplemental Table S9). When the strategies were ranked according to their effectiveness using 
the surface under cumulative ranking curve statistics, the three most effective interventions were: teleconsulta-
tion alone, followed by telecase-management plus telemonitoring and teleeducation plus telecase-management. 
Comparison-adjusted funnel plots for the network meta-analysis indicated very little evidence of asymmetry 
(Supplemental Figures S4–S5).
Secondary outcomes. Figure 2 presents the estimated effects of different telemedicine strategies on car-
diovascular outcomes. Across all outcomes examined, point estimates indicated that most telemedicine strat-
egies were generally similar to usual care (Supplemental Tables S8–S9). Five studies reported a decrease in the 
frequency of hypoglycaemia7,28–31 in the telemedicine group, while one study reported an increase32. There was 
no evidence that telemedicine reduced the risk of hypoglycaemia (risk differences: −0.20%; 95 CI: −0.57% to 
0.17%). In all nine studies which reported quality of life, no significant change (using either generic quality of 
life scale or diabetes specific quality of life scale) between groups were reported3,33–40. Similarly, pooled analysis 
showed no improvement in the quality of life in the Problem Area in Diabetes scale (MD: −2.18; −10.28 to 5.92).
Publication bias and Sensitivity analyses. Omission of each study sequentially did not lead to a signif-
icant change in the estimates of both primary as well as secondary outcomes, except for the exclusion of study 
by Shahid et al.41, which reduced the effectiveness of telemedicine in reducing HbA1c from −0.43% to −0.34% 
(95%CI: −0.41 to −0.27). Repeated analysis with fixed effect model did not significantly alter the results or het-
erogeneity (Supplemental Figure S5 and Table S10). No significant bias was observed using the Egger regression 
analysis (p = 0.36) but Begg rank-correlation showed evidence of small study effects (p < 0.01).
Discussion
This study is the largest and most comprehensive structured review to date on the effects of telemedicine. It pre-
sents evidence on the relative effectiveness of various telemedicine strategies for individuals with type 2 diabetes 
as well as factors which are associated with improved patient outcomes and those that do not. Despite the pres-
ence of substantial heterogeneity, telemedicine interventions were found to produce significantly better glycaemic 
outcomes than usual care using pairwise meta-analyses, and some of the changes were of clinical significance. 
This was similarly confirmed in the network meta-analysis. However, we did not note any significant effects on 
other outcomes such as quality of life, risk of hypoglycaemia, blood pressure and blood cholesterol.
The biggest potential of telemedicine lies in its ability to help people who cannot be accommodated with 
existing healthcare clinics due to geographical constraints or resources42. Results of our study suggest that tele-
medicine produced clinically meaningful reduction in HbA1c43, with an average reduction of between 0.37% and 
0.71%, depending on which strategies are used. Studies have shown that a 1% drop in HbA1c has been associated 
with a 10% reduction in diabetes-related death and 25% reduction in microvascular complications, with greater 
reductions when simultaneously targeting glucose, blood pressure and lipid control44,45. These could lead to a 
reduction in direct healthcare cost (through fewer visits to healthcare professionals, reduced absence from work 
and hospital admissions) as well as positive impacts on patients’ quality of life46.
Eligible studies
Dietician / Nutritionist 11
Others – lay person, social worker 20






Table 2. Baseline characteristics of included studies. Values are number of studies unless otherwise stated. 
IQR- Interquartile range, *Some studies may report the same strategy multiple times. †Some studies reported 
conducting the study in different intervention sites.
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mean difference (95% CI)
Glycosylated haemoglobin (%)
Usual care vs
Telemonitoring 14 1,577 71% [2] −0.44 (−1.63 to −0.07)
Teleconsultation 7 1,328 98% [44] −0.64 (−3.74 to −0.02)
Tele-education 26 4,211 81% [4] −0.36 (−0.97 to −0.07)
Telecase-management 8 2,620 97% [28] −0.28 (−2.87 to 0.13)
Telementoring 11 2,892 99% [253] −0.28 (−1.51 to 0.08)
Tele-education & 
telemonitoring 8 1,540 72% [2] −0.35 (−2.20 to −0.02)
Telecase-management & 
telemonitoring 9 1,194 84% [5] −0.54 (−2.44 to −0.06)
Tele-education & telecase-
management 9 1,409 96% [26] −0.31 (−2.66 to −0.02)
Telecase-management & 
Teleconsultation 1 40 NA [NA] −1.20 (−2.30 to −0.10)
Teleeducation vs
Telecase-management 1 100 NA [NA] −0.40 (−1.03 to 0.23)
Tele-education & telecase-
management 1 79 NA [NA] −0.16 (−0.70 to 0.38)
Telemonitoring vs Tele-education & telemonitoring 1 152 NA [NA] 0.02 (−0.37 to 0.41)
Fasting plasma glucose (mmol/L)
Usual care vs
Teleeducation 7 1393 79% [4] −0.67 (−1.23 to −0.11)
Telecase-management 3 494 61% [NA] −1.78 (−2.84 to −0.72)
Telemonitoring 7 566 41% [1] −0.90 (−1.32 to −0.49)
Telecase-management & 
Telemonitoring 3 167 0% [NA] −1.69 (−2.46 to −0.93)
Teleeducation & Telecase-
management 3 155 0% [NA] 0.04 (−0.79 to 0.87)
Teleeducation & 
Telemonitoring 1 100 NA [NA] −0.70 (−1.60 to 0.20)
Total cholesterol (mmol/L)
Usual care vs
Teleeducation 11 2,517 40% [1] −0.12 (−0.24 to 0.00)
Telecase-management 3 1,628 82% [NA] −0.02 (−0.47 to 0.43)
Telemonitoring 9 965 94% [15] 0.00 (−0.92 to 0.28)
Telementoring 3 859 0% [NA] 0.03 (0.02 to 0.04)
Teleeducation & 
Telemonitoring 1 100 NA [NA] −0.27 (−0.57 to 0.03)
Telecase-management & 
Telemonitoring 2 339 0% [NA] −0.22 (−0.42 to −0.01)
Teleeducation & Telecase-
management 2 117 84% [NA] 0.14 (−0.78 to 1.06)
Teleeducation vs Telecase-management 1 100 NA [NA] −0.08 (−0.45 to 0.29)
High-density lipoprotein (mmol/L)
Usual care vs
Teleeducation 10 1,593 35% [1] 0.01 (−0.02 to 0.03)
Telecase-management 2 246 0% [NA] 0.01 (−0.02 to 0.05)
Telemonitoring 9 938 15% [1] 0.00 (−0.11 to 0.03)
Teleconsultation 2 84 95% [NA] 0.48 (−0.39 to 1.35)
Telementoring 2 762 99% [NA] −0.06 (−0.20 to 0.08)
Teleeducation & Telecase-
management 1 53 NA [NA] 0.10 (−0.07 to 0.27)
Telecase-management & 
Telemonitoring 4 472 57% [NA] −0.13 (−0.26 to −0.01)
Teleeducation vs Telecase-management 1 100 NA [NA] −0.03 (−0.15 to 0.09)
Low-density lipoprotein (mmol/L)
Teleeducation 8 1,768 46% [1] 0.00 (−0.05 to 3.67)
Telecase-management 4 1,923 91% [NA] 0.08 (−0.22 to 0.37)
Teleconsultation 3 1,145 96% [NA] −0.19 (−0.47 to 0.09)
Telemonitoring 8 861 71% [2] −0.07 (−0.17 to 0.19)
Telementoring 3 1,091 99% [NA] −0.06 (−0.22 to 0.11)
Telecase-management & 
Telemonitoring 4 472 15% [NA] −0.06 (−0.24 to 0.12)
Teleeducation & Telecase-
management 1 359 NA [NA] 0.03 (0.02 to 0.04)
Continued
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mean difference (95% CI)
Teleeducation vs Telecase-management 1 100 NA [NA] −0.09 (−0.39 to 0.21)
Triglycerides (mmol/L)
Teleeducation 9 1,928 39% [1] −0.14 (−0.30 to −0.06)
Telecase-management 2 246 0% [NA] 0.04 (−0.07 to 0.15)
Teleconsultation 2 84 NA [NA] −0.08 (−0.36 to 0.19)
Telemonitoring 9 938 39% [1] −0.04 (−0.14 to 0.63)
Telementoring 1 628 NA [NA] 0.20 (0.15 to 0.25)
Teleeducation & 
Telemonitoring 1 100 NA [NA] −0.17 (−0.54 to 0.20)
Telecase-management & 
Telemonitoring 3 293 0% [NA] −0.24 (−0.50 to 0.02)
Teleeducation & Telecase-
management 2 117 0% [NA] −0.07 (−0.54 to 0.39)
Teleeducation vs Telecase-management 1 100 NA [NA] −0.02 (−0.50 to 0.46)
BMI (kg/m2)
Teleeducation 6 1,256 0% [0] 0.00 (−0.08 to 0.07)
Telecase-management 3 687 40% [NA] 1.10 (0.22 to 1.98)
Teleconsultation 3 611 40% [NA] 0.26 (−0.65 to 1.18)
Telemonitoring 6 778 91% [11] −0.98 (−2.26 to 0.31)
Telementoring 4 1,188 99% [NA] −0.40 (−1.32 to 0.52)
Teleeducation & 
Telemonitoring 3 261 50% [NA] −0.60 (−1.74 to 0.54)
Telecase-management & 
Telemonitoring 3 335 0% [NA] 0.14 (−0.23 to 0.52)
Teleeducation & Telecase-
management 2 247 0% [NA] 0.08 (−1.24 to 1.40)
Teleeducation vs Telecase-management 1 100 NA [NA] 0.00 (−2.53 to 2.53)
Systolic blood pressure (mm Hg)
Teleeducation 7 1,791 0% [0] −4.05 (−5.64 to −1.10)
Telecase-management 3 1,785 0% [NA] −2.65 (−4.62 to −0.68)
Teleconsultation 3 1,145 88% [NA] −0.29 (−2.68 to 2.10)
Telemonitoring 6 883 0% [0] −0.03 (−1.03 to 0.00)
Telementoring 5 1,536 96% [NA] 0.89 (−0.64 to 2.43)
Teleeducation & 
Telemonitoring 4 709 78% [NA] −3.91 (−10.07 to 2.25)
Telecase-management & 
Telemonitoring 5 520 0% [NA] −2.16 (−5.22 to 0.91)
Teleeducation & Telecase-
management 2 574 88% [NA] −0.74 (−8.81 to 7.33)
Teleeducation vs Telecase-management 1 100 NA [NA] −5.76 (−12.15 to 0.63)
Diastolic blood pressure (mm Hg)
Teleeducation 6 1,751 56% [1] −1.93 (−4.04 to −0.22)
Telecase-management 3 1,785 0% [NA] −1.51 (−2.45 to −0.57)
Teleconsultation 2 510 88% [NA] −3.72 (−8.80 to 1.36)
Telemonitoring 5 658 40% [NA] −0.97 (−2.91 to 0.97)
Telementoring 4 1,237 98% [NA] 1.16 (−0.13 to 2.45)
Teleeducation & 
Telemonitoring 3 509 17% [NA] −0.82 (−2.94 to 1.30)
Telecase-management & 
Telemonitoring 5 520 0% [NA] −1.72 (−3.59 to 0.15)
Teleeducation & Telecase-
management 1 215 NA [NA] 3.00 (−0.10 to 6.10)
Teleeducation vs Telecase-management 1 100 NA [NA] −3.30 (−8.33 to 1.73)
Quality of life (Problem Areas in Diabetes)
Intervention 2 194 53% [NA] −2.18 (−10.28 to 5.92)
Hypogylcaemia (% of patients affected)
Intervention 2 101 80% −0.20 (−0.57 to 0.17)*
Diabetes self-efficacy Scale (DSES)
Intervention 3 945 58% [NA] 0.46 (−0.05 to 0.97)
Table 3. Results of pairwise meta-analysis for primary and secondary outcomes of different telemedicine 
strategies. *Mean difference.
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Our findings were less clear in several areas. Due to the limited number of studies included in each subgroup, 
it was not possible to clearly identify whether different technology used to support telemedicine (e.g. computer, 
SMS, smartphones), use of interactive or non-interactive technology, administrator of intervention (e.g. nurse, 
physician) or a combination of these factors had led to improved results. We were also unable to assess these 
interactions in our meta-regression analyses due to the small number of trials for each outcomes as well as the 
substantial heterogeneity of results. Most of the trials included had only reported HbA1c concentrations, with 
very few reporting other key aspects of diabetes managements. As such, we urge caution when interpreting results 
for other secondary outcomes, though our preliminary analyses suggest some consistency across outcomes. The 
evidences presented in this review are in agreement with other systematic reviews which suggest that telemedi-
cine is useful in improving patient care (Supplemental Table S11), with similar magnitude of improvements. The 
present review also showed that telemedicine strategies were associated with additional clinical benefits beyond 
glycaemic control and these included improvement in blood pressure and triglyceride levels.
In our review, we also found that the definition of usual care was inconsistent across all studies. These varied 
from regular clinic visit every 3 to 6 months to a more intensive form of usual care, including drug therapy review, 
dietary counseling and health coaching. While we attempted to stratify the various elements that constituted to 
usual care, the descriptions provided by most studies were not sufficiently detailed. As such, it is possible that 
the relative effectiveness of telemedicine noted in this study maybe underestimated, especially if implemented in 
routine clinical practice.
In the present review, a high level of clinical heterogeneity of studies was found and this was probably due to 
the diverse patient population recruited. Such variation is expected for an analysis of complex intervention and 
hence, a meta-regression approach was utilized in the present study. This study found that study location was a 
significant predictor for larger reductions in HbA1c, explaining 31% of the heterogeneity. This could be attributed 
to several reasons. Firstly, the different settings where these studies were conducted could mean that some of the 
contextual (such as health care system) and cultural factors may have played a role in the implementation process 
and thus affected the outcomes30,47. In addition, most of the studies conducted in Asian countries had smaller 
sample sizes and were conducted over a shorter period of time. This might have increased adherence to the inter-
vention and hence a better success rate. Similarly, the implementation of intervention could also be more intense 
in studies with smaller sample size. Lastly, there could be variation in the dissemination and implementation 
dimensions of such intervention between the continents.
The present study has several important limitations that warrant mentioning. Firstly, the high level of hetero-
geneity in the results suggests that the results should be interpreted with caution. This could be attributed to the 
variation in types of telemedicine technology used, population studied as well as healthcare personals involved. 
Secondly, as with all meta-regression analyses, we used summary data which made the findings vulnerable to eco-
logical fallacy, and thus these findings may not be applicable to an individual. In addition, there is limited statisti-
cal power with these analyses48. Thirdly, the lack of long term follow-up (minimum 1 to 2 years) studies may limit 
the interpretation of the results to only short-term effects of included interventions and not long-term outcomes 
such as mortality. The sustainability and cost-effectiveness of these interventions may also be questionable. Most 
of the results used in the meta-analyses were based upon per protocol analysis, which may have resulted in higher 
result estimates. Due to the complexity of interventions involved, compounded by a lack of description in most 
studies, misclassified interventions could not be ruled out. To minimize the misclassification of interventions, 
two authors independently assessed each study and reviewed other pertaining report of the same study to obtain 
additional information. This technique has been found to improve reporting completeness by nearly 65%49. The 
lack of reporting for many trials had also limited our ability to perform several subgroup analyses such as roles 
Figure 1. Network meta-analysis estimates of change in glycated haemoglobin in adults with type 2 diabetes.
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of interventionist and healthcare setting on the impact of telemedicine. Finally, only a few studies had provided 
data on adverse events, quality-of-life measures or even cost-effectiveness analyses and hence, the data should be 
interpreted with caution.
Investments in information technology will increase over the next few years. The network meta-analysis in 
the present study substantiates that individual focused telemedicine intervention such as education, small group 
discussion as well as structural changes (replacing clinic visits with remote consultations) is effective in reducing 
HbA1c. Additionally, it provides some important insights for future research development and implementation. 
This includes a more detailed description of the methodology as well as target other clinical outcomes besides 
HbA1c, such as quality of life and cost savings. Such information is vital for policy-makers to tailor their choice 
Figure 2. Network meta-analysis estimates of changes in secondary cardiovascular outcomes of different 
telemedicine strategies compared to usual care.
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of interventions to the desired outcomes based on the best available evidence, maximizing available resources in 
a local healthcare context. The challenge, however, remains as to how to ensure such evidence does not get lost 
in translation and can be adopted within reasonable timeframe. Some strategies may include the promotion of 
access and usage by practitioners through capacity building, dissemination of intervention materials and engag-
ing stakeholders in the planning phase.
Conclusion
The greatest potential of telemedicine lies in providing easy access especially by people in rural areas where 
healthcare resources are limited. Assessing the acceptability and implementation challenges of telemedicine in 
resource poor areas is an important next step to accelerate translation. This can lead to reduced healthcare cost 
and improved patient outcomes.
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